Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial

被引:78
作者
Azizi, Fereidoun [1 ]
Amouzegar, Atieh [1 ]
Tohidi, Maryam [2 ]
Hedayati, Mehdi [3 ]
Khalili, Davood [2 ,4 ]
Cheraghi, Leila [4 ]
Mehrabi, Yadollah [5 ]
Takyar, Miralireza [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, POB 19395-4763, Tehran 1985717413, Iran
[2] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Prevent Metab Disorders Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Cellular & Mol Endocrine Res Ctr, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Dept Epidemiol & Biostat, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Epidemiol & Biostat, Tehran, Iran
关键词
long-term; methimazole; Graves' disease; remission rates; ANTITHYROID DRUG-TREATMENT; HYPERTHYROIDISM; EXPOSURE; IODINE; RISK;
D O I
10.1089/thy.2019.0180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length methimazole therapy. We also sought variables associated with relapse following the latter. Methods: We enrolled 302 consecutive patients with untreated first episodes of Graves' hyperthyroidism. After 18-24 months of methimazole, 258 patients (85.4%) were randomized to an additional 36-102-month courses ("long-term group": n = 130; scheduled total time on methimazole: 60-120 months) or discontinuation of methimazole ("conventional group": n = 128). Patients were followed 48 months postmethimazole cessation. We performed Cox proportional hazards modeling to identify factors associated with relapse after conventional courses. Results: Methimazole was given for 95 +/- 22 months in long-term patients and 19 +/- 3 months in the conventional group. Fourteen patients experienced cutaneous reactions and 2 liver enzyme elevations during the first 18 months of treatment; no further methimazole-related reactions were observed despite therapy for up to another 118 months. Hyperthyroidism recurred within 48 months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877 CD28 polymorphism or the DQB1-05 HLA polymorphism were independently associated with relapse. Conclusion: Administration of low-dose methimazole for a total of 60-120 months safely and effectively treats Graves' hyperthyroidism, with much higher remission rates than those attained by using conventional 18-24-month courses.
引用
收藏
页码:1192 / 1200
页数:9
相关论文
共 27 条
[1]   Antithyroid drug regimen for treating Graves' hyperthyroidism [J].
Abraham, Prakash ;
Avenell, Alison ;
McGeoch, Susan C. ;
Clark, Louise F. ;
Bevan, John S. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01)
[2]   ANTITHYROID DRUGS AND GRAVES-DISEASE - A PROSPECTIVE RANDOMIZED EVALUATION OF THE EFFICACY OF TREATMENT DURATION [J].
ALLANNIC, H ;
FAUCHET, R ;
ORGIAZZI, J ;
MADEC, AM ;
GENETET, B ;
LORCY, Y ;
LEGUERRIER, AM ;
DELAMBRE, C ;
DERENNES, V .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (03) :675-679
[3]   Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: A population based study [J].
Amouzegar, A. ;
Delshad, H. ;
Mehran, L. ;
Tohidi, M. ;
Khafaji, F. ;
Azizi, F. .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2013, 36 (11) :950-954
[4]   Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine [J].
Azizi, F ;
Ataie, L ;
Hedayati, M ;
Mehrabi, Y ;
Sheikholeslami, F .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (05) :695-701
[5]   Long-Term Antithyroid Drug Treatment: A Systematic Review and Meta-Analysis [J].
Azizi, Fereidoun ;
Malboosbaf, Ramin .
THYROID, 2017, 27 (10) :1223-1231
[6]   A 2013 European survey of clinical practice patterns in the management of Graves' disease [J].
Bartalena, L. ;
Burch, H. B. ;
Burman, K. D. ;
Kahaly, G. J. .
CLINICAL ENDOCRINOLOGY, 2016, 84 (01) :115-120
[7]   Graves' Disease and Toxic Nodular Goiter Are Both Associated with Increased Mortality But Differ with Respect to the Cause of Death: A Danish Population-Based Register Study [J].
Brandt, Frans ;
Thvilum, Marianne ;
Almind, Dorthe ;
Christensen, Kaare ;
Green, Anders ;
Hegedus, Laszlo ;
Brix, Thomas Heiberg .
THYROID, 2013, 23 (04) :408-413
[8]   Antithyroid Drugs-The Most Common Treatment for Graves' Disease in the United States: A Nationwide Population-Based Study [J].
Brito, Juan P. ;
Schilz, Stephanie ;
Ospina, Naykky Singh ;
Rodriguez-Gutierrez, Rene ;
Maraka, Spyridoula ;
Sangaralingham, Lindsey R. ;
Montori, Victor M. .
THYROID, 2016, 26 (08) :1144-1145
[9]   A 2011 Survey of Clinical Practice Patterns in the Management of Graves' Disease [J].
Burch, Henry B. ;
Burman, Kenneth D. ;
Cooper, David S. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (12) :4549-4558
[10]   Eighteen Years of Continuously Sustained Elimination of Iodine Deficiency in the Islamic Republic of Iran: The Vitality of Periodic Monitoring [J].
Delshad, Hossien ;
Amouzegar, Atieh ;
Mirmiran, Parvin ;
Mehran, Ladan ;
Azizi, Fereidoun .
THYROID, 2012, 22 (04) :415-421